Evidence map›Paper›PMID 39000538›Full record

ArticleInternational journal of molecular sciences2024

Alternatives to Conventional Topical Dosage Forms for Targeted Skin Penetration of Diclofenac Sodium.

Benjamin Gavinet, Séverine Sigurani, Christine Garcia, Alicia Roso

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjamin GavinetResearch & Innovation, Seppic, 127 Chemin de la Poudrerie, 81100 Castres, France.
Séverine SiguraniResearch & Innovation, Seppic, 127 Chemin de la Poudrerie, 81100 Castres, France.
Christine GarciaResearch & Innovation, Seppic, 127 Chemin de la Poudrerie, 81100 Castres, France.
Alicia RosoResearch & Innovation, Seppic, 127 Chemin de la Poudrerie, 81100 Castres, France.ORCID 0000-0002-9894-2623

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin penetration of an active pharmaceutical ingredient is key to developing topical drugs. This penetration can be adjusted for greater efficacy and/or safety through the selection of dosage form. Two emerging dosage forms, cream-gel and gel-in-oil emulsion, were tested for their ability to deliver diclofenac into the skin, with the target of maximising skin retention while limiting systemic exposure. Prototypes with varying amounts of solvents and emollients were formulated and evaluated by in vitro penetration testing on human skin. Cream-gel formulas showed better skin penetration than the emulgel benchmark drug even without added solvent, while gel-in-oil emulsions resulted in reduced diffusion of the active into the receptor fluid. Adding propylene glycol and diethylene glycol monoethyl ether as penetration enhancers resulted in different diclofenac penetration profiles depending on the dosage form and whether they were added to the disperse or continuous phase. Rheological characterisation of the prototypes revealed similar profiles of cream-gel and emulgel benchmark, whereas gel-in-oil emulsion demonstrated flow characteristics suitable for massaging product into the skin. This study underlined the potential of cream-gel and gel-in-oil emulsions for adjusting active penetration into the skin, broadening the range of choices available to topical formulation scientists.

Indexed as

Administration, CutaneousDiclofenacEmulsionsSkinSkin AbsorptionAdministration, TopicalAnti-Inflammatory Agents, Non-SteroidalEmollientsGelsHumansRheologyAnti-Inflammatory Agents, Non-SteroidalDiclofenacEmollientsEmulsionsGelscream–geldiclofenacgel-in-oil emulsionin vitro permeation testskin penetrationtopical formulation

Identifiers

PMID39000538
PMCPMC11242280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.